ERG2 Antibody

What is EGR2 and what are its primary biological functions?

EGR2 is a zinc finger-containing transcription factor that binds to specific DNA regions to control gene expression. It plays several crucial roles in mammalian biology:

• In the immune system, EGR2 is important for the development of T cells and NKT cells, being predominantly expressed in the thymus .

• EGR2 is upregulated in T cells following TCR cross-linking and appears to antagonize T cell activation while promoting apoptosis under certain conditions .

• In the nervous system, EGR2 plays a vital role in hindbrain segmentation by regulating the expression of homeobox-containing genes .

• EGR2 regulates Schwann cell myelination by controlling genes involved in myelin formation and maintenance .

• It functions as an E3 SUMO-protein ligase, helping SUMO1 conjugation to its coregulators NAB1 and NAB2, which down-regulates its own transcriptional activity .

Recent research has revealed that EGR2 also controls homing and pathogenicity of certain T cell populations, suggesting its broader role in immune regulation and potential involvement in autoimmune disorders .

What experimental applications are EGR2 antibodies validated for?

EGR2 antibodies have been validated for several key experimental applications in immunology and cell biology research:

• Flow cytometry: EGR2 antibodies have been rigorously tested for intracellular staining followed by flow cytometric analysis of stimulated mouse splenocytes . The erongr2 monoclonal antibody (clone erongr2) specifically has been validated using the Foxp3/Transcription Factor Staining Buffer Set for optimal results .

• Western blotting: Anti-EGR2 antibodies such as the OTI1F10 clone have been validated for detecting EGR2 protein expression in human and African green monkey samples via Western blot analysis .

• Immunocytochemistry/Immunofluorescence (ICC/IF): Several antibodies have been confirmed suitable for visualizing EGR2 in fixed cells and tissues .

• Chromatin immunoprecipitation (ChIP): Anti-EGR2 antibodies have been employed in ChIP assays to demonstrate binding to regulatory regions of anergy-associated genes, confirming EGR2's direct transcriptional regulation activity .

When selecting antibodies for any of these applications, researchers should verify that the specific clone has been validated for their species of interest and experimental system.

How should I optimize EGR2 antibody concentration for flow cytometry?

Optimizing EGR2 antibody concentration for flow cytometry requires careful titration and protocol adjustment:

Follow this methodological approach:

• Perform a titration series (typically 0.05-0.5 μg per test) using stimulated cells known to express EGR2 as a positive control.

• Cell numbers can range from 10^5 to 10^8 cells per test but should be determined empirically for your specific cell type .

• Always use appropriate fixation and permeabilization methods, such as the Foxp3/Transcription Factor Staining Buffer Set (which has been validated with EGR2 antibodies) .

• Include unstained controls and isotype controls to establish background fluorescence levels.

• For the erongr2 clone conjugated to APC, use red laser excitation (633-647 nm) and emission detection at approximately 660 nm .

Remember that EGR2 expression can be upregulated in T cells following TCR crosslinking or stimulation with PMA and ionomycin, which can be useful for generating positive controls in your optimization experiments .

How can I design experiments to investigate EGR2's role in T cell anergy?

Investigating EGR2's role in T cell anergy requires sophisticated experimental approaches that manipulate EGR2 expression or function:

Experimental design framework:

• Genetic manipulation models:

  • Utilize conditional knockout systems such as CD4-Cre × Egr2 flox/flox mice, which have been shown to eliminate Egr2 expression specifically in T cells .

  • Alternatively, use adenoviral Cre delivery in Egr2 flox/flox T cells for in vitro deletion models .

• Anergy induction protocols:

  • In vitro: Treat T cells with anti-CD3 without costimulation to induce anergy, then measure IL-2 production upon restimulation .

  • In vivo: Administer superantigens like staphylococcal enterotoxin B (SEB), then isolate T cells 7 days later and assess their responsiveness .

• Functional readouts:

  • Measure IL-2 production as a primary readout of T cell anergy resistance .

  • Evaluate ERK phosphorylation, which is normally blunted in anergic cells but restored with Egr2 deletion .

  • Assess expression of anergy-associated genes including DGK-ζ, Cbl-b, Itch, Tob1, and Dtx1, which are regulated by EGR2 .

• Mechanistic analysis:

  • Perform ChIP assays to detect EGR2 binding to regulatory regions of anergy-associated genes .

  • Use quantitative RT-PCR to measure how EGR2 manipulation affects the expression of these downstream targets .

Research has demonstrated that EGR2-deficient T cells are resistant to both in vitro and in vivo anergy induction protocols, highlighting EGR2's essential role in this important tolerance mechanism .

What are the best practices for analyzing EGR2 expression in T helper cell differentiation?

When analyzing EGR2 expression during T helper cell differentiation, researchers should implement these best practices:

• Cell isolation and polarization:

  • Isolate naïve CD4+ T cells (CD4+CD44lowCD62Lhigh) using magnetic sorting or flow cytometry.

  • Culture under specific polarizing conditions:

    • TH17: IL-6 + TGF-β1 (note that EGR2 has been shown to promote TH17 lineage commitment)

    • Compare with other TH subsets (TH1, TH2) to establish specificity of EGR2's effects.

• Expression analysis methods:

  • Flow cytometry: Perform intracellular staining for EGR2 along with lineage-specific transcription factors (RORγt for TH17 cells). The erongr2 clone antibody is suitable for this purpose .

  • Western blotting: Use anti-EGR2 antibodies (1:1,000 dilution has been reported to be effective) .

  • qRT-PCR: Monitor Egr2 transcript levels alongside lineage-defining genes.

• Functional validation:

  • Use retroviral transduction of Egr2 (Egr2-RV) to rescue or overexpress EGR2 in different T cell populations .

  • Assess how EGR2 expression correlates with cytokine production (IL-17 for TH17 cells) .

  • Investigate the relationship between EGR2 and lineage-defining transcription factors like RORγt .

• Critical controls:

  • Include Rorc+/- cells to test the dependence of EGR2's effects on RORγt expression .

  • Use Rorc-RV as a positive control for TH17 differentiation .

Research has demonstrated that EGR2 promotes TH17 cell differentiation in a RORγt-dependent manner, indicating a complex relationship between these transcription factors in T cell fate decisions .

How can I validate the specificity of an EGR2 antibody?

Validating EGR2 antibody specificity requires a multi-tiered approach to ensure reliable experimental results:

• Genetic validation:

  • Test the antibody on samples from EGR2 knockout models (e.g., CD4-Cre × Egr2 flox/flox mice for T cells) .

  • Confirm absence of signal in EGR2-deficient cells via immunoblotting and flow cytometry .

  • Use siRNA or CRISPR-Cas9 knockdown of EGR2 in cell lines as an alternative validation approach.

• Cross-reactivity assessment:

  • Test against related family members, particularly EGR3, which shares structural similarities. The erongr2 monoclonal antibody has been shown not to cross-react with EGR3 based on immunoblot analysis .

  • Examine antibody reactivity in tissues known to express (thymus, nervous system) or not express EGR2.

• Expression pattern confirmation:

  • Verify that antibody detects expected expression patterns: upregulation in T cells following TCR cross-linking or PMA/ionomycin stimulation .

  • Confirm modest staining of subpopulations of T cells and B cells in freshly isolated spleen cells, consistent with known EGR2 biology .

• Technical validation:

  • Perform peptide competition assays using the immunizing peptide.

  • Compare multiple antibodies targeting different epitopes of EGR2.

  • Use recombinant EGR2 protein as a positive control for Western blot analysis.

• Functional correlation:

  • Correlate antibody staining with known EGR2 functions, such as promotion of TH17 differentiation or regulation of T cell anergy .

Researchers should maintain a validation file documenting these specificity tests to ensure reproducible and reliable results across experiments.

What factors might affect EGR2 antibody performance in flow cytometry?

Several critical factors can significantly impact EGR2 antibody performance in flow cytometric applications:

• Fixation and permeabilization conditions:

  • EGR2 is a nuclear transcription factor, requiring robust nuclear permeabilization for antibody access.

  • The Foxp3/Transcription Factor Staining Buffer Set has been specifically validated with EGR2 antibodies .

  • Alternative fixation methods may yield suboptimal results due to epitope masking or insufficient nuclear access.

• Cell activation status:

  • EGR2 expression is dynamically regulated and upregulated following TCR cross-linking or stimulation with PMA and ionomycin .

  • Timing of analysis after stimulation is critical—expression patterns change over the course of activation.

  • Resting cells may show lower EGR2 levels, potentially below detection threshold.

• Antibody clone and fluorophore selection:

  • Different clones (e.g., erongr2) have varying sensitivity and specificity profiles .

  • The fluorophore conjugate affects sensitivity—APC conjugates require red laser (633-647 nm) excitation .

  • Spectral overlap with other fluorophores in your panel may necessitate proper compensation.

• Protocol technical factors:

  • Filtration quality: Using 0.2 μm post-manufacturing filtered antibody preparations ensures consistent performance .

  • Antibody concentration: Titration is essential, with ≤0.25 μg per test recommended as a starting point .

  • Cell density: Varying from 10^5 to 10^8 cells/test affects staining efficiency .

• Tissue/cell source considerations:

  • T cells and NKT cells show different baseline expression levels .

  • Different mouse strains may exhibit varying EGR2 expression levels.

  • Human vs. mouse samples require species-specific antibody validation.

When troubleshooting, systematically adjust one variable at a time while maintaining appropriate positive controls (stimulated splenocytes) and negative controls (isotype antibodies and unstained cells).

How do I interpret conflicting EGR2 expression data between different experimental approaches?

Interpreting conflicting EGR2 expression data requires a systematic analytical approach:

• Method-specific considerations:

  • Flow cytometry vs. Western blot: Flow cytometry provides single-cell resolution but may have sensitivity limitations; Western blot measures total protein but lacks cellular resolution. Disparities could reflect heterogeneous expression within a population .

  • Protein vs. RNA detection: Discrepancies between RT-PCR and protein detection methods might indicate post-transcriptional regulation of EGR2.

  • Antibody epitope differences: Different antibodies may recognize distinct EGR2 epitopes that are differentially accessible depending on protein conformation or interactions .

• Biological variables to consider:

  • Temporal dynamics: EGR2 expression changes rapidly following stimulation—ensure timepoints are comparable between experiments .

  • Cell activation status: TCR crosslinking, PMA/ionomycin stimulation dramatically affects EGR2 levels .

  • Cell subpopulations: EGR2 expression varies between T cell subsets and developmental stages .

• Resolution approaches:

  • Orthogonal validation: Confirm findings using independent techniques (e.g., if flow cytometry and Western blot conflict, add immunofluorescence microscopy).

  • Single-cell analysis: Use flow cytometry or single-cell RNA-seq to resolve population heterogeneity that might explain bulk measurement discrepancies.

  • Genetic validation: Use EGR2-deficient cells as definitive negative controls to determine assay specificity .

  • Standardized positive controls: Include cells with known EGR2 expression (e.g., PMA/ionomycin-stimulated splenocytes) .

• Technical validation:

  • Verify antibody specificity using the approaches outlined in question 6.

  • Examine how sample processing might affect epitope preservation differently across methods.

When publishing, transparently report these validation steps and acknowledge limitations of each methodology to strengthen interpretation of seemingly conflicting data.

What controls should I include when studying EGR2's role in T cell anergy and autoimmunity?

When investigating EGR2's role in T cell anergy and autoimmunity, comprehensive controls are essential for rigorous interpretation:

• Genetic controls:

  • Complete knockout models: CD4-Cre × Egr2 flox/flox mice provide T cell-specific deletion .

  • Conditional systems: Cell type-specific deletion (e.g., Egr2ΔIL17A mice where Egr2 is deleted only in IL-17A-producing cells) .

  • Heterozygous controls: Include Egr2+/- to assess gene dosage effects.

  • Wild-type littermates: Essential for proper comparison in disease models, as Egr2f/f littermates serve as appropriate controls .

• Experimental design controls:

  • In vitro anergy models:

    • Treatment control: Compare anti-CD3 alone (anergy-inducing) vs. anti-CD3+anti-CD28 (activating) .

    • Empty vector controls for Cre-delivery experiments .

  • In vivo models:

    • Vehicle controls (PBS) for superantigen (SEB) treatment .

    • Alternative immunization protocols in EAE models to verify specificity .

• Functional readout controls:

  • Signaling pathway verification: Measure ERK phosphorylation, which is blunted in anergic cells but restored with Egr2 deletion .

  • Gene expression benchmarks: Measure anergy-associated genes (DGK-ζ, Cbl-b, Itch, Tob1, Dtx1) whose expression depends on EGR2 .

  • Cytokine production: IL-2 measurement serves as a functional readout of anergy resistance .

• Cell type controls:

  • For T helper cell studies, compare effects across TH1, TH2, and TH17 lineages.

  • For CNS inflammation models, analyze both infiltrating T cells and resident neural cells .

• Technical controls:

  • Antibody validation: Verify EGR2 antibody specificity using EGR2-deficient cells.

  • ChIP specificity: Include IgG controls and non-target genes in ChIP experiments examining EGR2 binding to anergy-associated genes .

These comprehensive controls enable confident attribution of phenotypes to EGR2 function rather than experimental artifacts or compensatory mechanisms.

How is EGR2 implicated in controlling T cell pathogenicity in autoimmune diseases?

EGR2's role in T cell pathogenicity and autoimmune conditions represents a frontier in immunology research:

Recent investigations have revealed that EGR2 plays a critical role in controlling the pathogenicity of T cells in autoimmune conditions, particularly in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis:

• Expression patterns in inflammatory conditions:

  • Approximately 30% of CNS-infiltrating CD4+ T cells express EGR2 protein at the peak of EAE disease .

  • This suggests EGR2 marks a significant subset of pathogenic T cells involved in autoimmune neuroinflammation.

• Genetic evidence for pathogenic role:

  • EAE induced by MOG35-55 peptide immunization is attenuated in Egr2ΔT mice (T cell-specific deletion) .

  • Similarly, disease is reduced in Egr2ΔIL17A mice, where Egr2 is specifically deleted in IL-17A-producing cells .

  • This indicates EGR2 plays a functional role in promoting pathogenicity, particularly in TH17 cells.

• Mechanistic insights:

  • EGR2 promotes TH17 lineage commitment in a RORγt-dependent manner .

  • Transduction of Egr2-RV (retrovirus) can restore TH17 lineage commitment in Rorc+/- CD4+ T cells .

  • This suggests EGR2 works in cooperation with RORγt to drive the differentiation of pathogenic TH17 cells.

• Adoptive transfer models:

  • The passive transfer model of EAE using 2D2 T cells (MOG-specific TCR transgenic) provides additional evidence for EGR2's role .

  • This experimental approach allows tracking of antigen-specific T cells and assessment of how EGR2 influences their pathogenic potential.

These findings point to EGR2 as a potential therapeutic target in autoimmune diseases, particularly those mediated by pathogenic TH17 cells. Future research directions may include:

• Developing strategies to selectively inhibit EGR2 in pathogenic T cells

• Investigating how EGR2 balances its roles in both promoting T cell tolerance (through anergy) and enhancing pathogenicity (through TH17 differentiation)

• Exploring EGR2 expression as a biomarker for autoimmune disease activity or treatment response

What methodological approaches can detect the interaction between EGR2 and other transcription factors?

Investigating EGR2's interactions with other transcription factors requires sophisticated molecular techniques:

• Chromatin Immunoprecipitation (ChIP) approaches:

  • ChIP-seq: Use anti-EGR2 antibodies to immunoprecipitate EGR2-bound chromatin, followed by next-generation sequencing to identify genome-wide binding sites. This has revealed EGR2 binding to regulatory regions of anergy-associated genes .

  • Sequential ChIP (Re-ChIP): Perform two rounds of immunoprecipitation (first with anti-EGR2, then with antibodies against potential partner transcription factors) to identify regions co-occupied by both factors.

  • ChIP-qPCR: Target specific loci to quantitatively assess EGR2 binding to regulatory regions of interest genes, such as HOXA4, HOXB2, HOXB3, and ERBB2 .

• Protein-protein interaction methods:

  • Co-immunoprecipitation (Co-IP): Use anti-EGR2 antibodies to pull down EGR2 complexes, followed by Western blotting to detect associated transcription factors.

  • Proximity ligation assay (PLA): Visualize protein-protein interactions in situ using antibodies against EGR2 and potential partners, generating fluorescent signals only when proteins are in close proximity.

  • FRET/BRET: Employ fluorescence or bioluminescence resonance energy transfer to detect direct interactions between tagged EGR2 and partner proteins.

• Functional interaction assays:

  • Reporter gene assays: Assess how EGR2 and potential partner transcription factors cooperatively regulate target gene expression using reporter constructs containing EGR2-binding elements.

  • Gene expression analysis in genetic models: Compare gene expression profiles in wild-type, EGR2-deficient, partner-deficient, and double-deficient cells to identify cooperatively regulated genes.

  • Mutagenesis studies: Introduce mutations in EGR2 binding sites (e.g., EGR2A 5'-CTGTAGGAG-3' and EGR2B 5'-ATGTAGGTG-3') to assess functional relevance of binding .

• Advanced genomic approaches:

  • CUT&RUN or CUT&Tag: These techniques offer higher resolution than traditional ChIP for mapping transcription factor binding sites.

  • Single-cell multi-omics: Combine single-cell ATAC-seq with RNA-seq to correlate chromatin accessibility at EGR2 binding sites with gene expression.

  • HiChIP: Map long-range chromatin interactions mediated by EGR2 and partner transcription factors.

The relationship between EGR2 and RORγt in TH17 differentiation represents an important application of these methods, as EGR2 promotes TH17 lineage commitment in a RORγt-dependent manner . Similarly, understanding how EGR2 interacts with factors regulating hindbrain segmentation and Schwann cell myelination remains an active area of investigation .

How can I design experiments to study EGR2's E3 SUMO-protein ligase activity?

Studying EGR2's E3 SUMO-protein ligase activity requires specialized experimental approaches:

• In vitro SUMOylation assays:

  • Recombinant protein system: Express and purify recombinant EGR2, SUMO1, SUMO-activating enzyme (E1), SUMO-conjugating enzyme (E2), and potential substrates (NAB1 and NAB2) .

  • Reaction components: Set up reactions containing ATP, recombinant proteins, and buffer systems.

  • Detection methods: Analyze SUMOylation by Western blotting using anti-SUMO antibodies or antibodies specific for the substrate.

  • Control reactions: Include reactions lacking ATP, E1, E2, or EGR2 to confirm specificity.

• Cellular SUMOylation detection:

  • Co-expression systems: Transfect cells with tagged versions of EGR2, SUMO1, and substrates (NAB1 and NAB2) .

  • Immunoprecipitation: Pull down substrates and detect SUMOylation by Western blotting.

  • SUMO-site mapping: Use mass spectrometry to identify specific lysine residues on NAB1 and NAB2 that are SUMOylated by EGR2.

  • Mutational analysis: Create lysine-to-arginine mutations at potential SUMOylation sites to verify specific modification sites.

• Functional consequences assessment:

  • Transcriptional reporter assays: Compare EGR2 transcriptional activity in the presence of wild-type versus SUMOylation-deficient NAB1/NAB2 .

  • Protein-protein interaction analysis: Investigate how SUMOylation affects the interaction between EGR2 and its coregulators using co-IP or other interaction assays.

  • Subcellular localization studies: Determine if SUMOylation alters the nuclear localization or subnuclear distribution of NAB proteins.

• Physiological relevance:

  • Conditional expression systems: Develop cellular models expressing SUMOylation-deficient NAB proteins to assess physiological outcomes.

  • Gene expression profiling: Compare transcriptional profiles when EGR2's E3 SUMO-ligase activity is intact versus compromised.

  • Context dependency: Investigate how different cellular stresses or stimuli affect EGR2-mediated SUMOylation.

• Technical considerations:

  • Use cell types relevant to EGR2 biology (T cells, Schwann cells) .

  • Include appropriate antibody controls to ensure specific detection of SUMOylated species.

  • Consider the transient nature of SUMOylation by using deSUMOylase inhibitors in experiments.

This experimental framework will help elucidate how EGR2's E3 SUMO-protein ligase activity contributes to the down-regulation of its own transcriptional activity through the SUMOylation of its coregulators NAB1 and NAB2 , potentially revealing novel regulatory mechanisms in T cell development and myelination.